An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects 2 to < 5 Years of Age With Osteogenesis Imperfecta Types I, III or IV
Details
Age
Child
Eligibility
Diagnosis of Osteogenesis Imperfecta with more than 1 fracture in the past 12 months, 2 fractures in past 24 months, or 1 femur, tibia, or humerus fracture in last 24 months AND between ages 2 to <5
Type of Study
Treatment
Scope
National
Locations
Childrens Hospital Colorado
Principal Investigator
Klane White, MD, MSc
Study ID
Protocol Number: 23-0369
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers